Why Pacific Biosciences of California, Inc.’s (PACB) Stock Is Down 10.09%
As of Monday, October 12, Pacific Biosciences of California, Inc.’s PACB share price has dipped by 10.09%, which has ...
Model output · Signal date 2026-10-16
Pacific Biosciences Of California, Inc. (PACB) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 5172 stocks scored
Rank correlation · 90D
-14.0%
Spearman, 357 dates
Market Cap
$538M
small-cap · #12 of 25 peers
Summary
Pacific Biosciences Of California, Inc. (PACB) stock forecast summary
Our AI ranks Pacific Biosciences Of California, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Pacific Biosciences Of California, Inc. is a small-cap company with a market capitalization of $538M. It ranks number 12 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
For PACB, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -14.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -2.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PACB included.
Follow PACB freePrice
PACB price chart and AI forecast
Cross-section · 2026-10-16
How PACB ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Pacific Biosciences Of California, Inc. (PACB) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
Valuation & Market
| Metric | PACB | Rank |
|---|---|---|
| Market Cap | $538M | 12/25 |
| EPS | $-0.38 | – |
| Revenue/Share | $0.51 | – |
| FCF/Share | $-0.40 | – |
Profitability & Margins
| Metric | PACB | Rank |
|---|---|---|
| ROA | -17.5% | 11/20 |
| ROIC | -19.5% | 13/20 |
| Gross Margin | 36.4% | 16/19 |
| Operating Margin | -83.5% | 14/21 |
| Net Margin | -82.5% | 14/19 |
| EBT Margin | -82.0% | 17/22 |
| Tax Rate | -0.6% | – |
Financial Health
| Metric | PACB | Rank |
|---|---|---|
| Current Ratio | 4.92x | 8/25 |
| Quick Ratio | 4.03x | 7/24 |
| Interest Coverage | -5.0x | 10/21 |
| Working Capital | $270M | 11/25 |
Cash Flow
| Metric | PACB | Rank |
|---|---|---|
| Operating Cash Flow | -$118M | 23/24 |
| Free Cash Flow | -$123M | 19/20 |
| Capital Spending | -$5M | 11/20 |
| FCF/Sales | -77.5% | 15/19 |
| CapEx/Sales | 3.4% | 7/19 |
Operational Efficiency
| Metric | PACB | Rank |
|---|---|---|
| Asset Turnover | 0.21x | 18/20 |
| Receivables Turnover | 5.1x | 15/19 |
| Inventory Turnover | 1.7x | 14/19 |
| Fixed Assets Turnover | 5.9x | 9/21 |
| Days Sales Outstanding | 71 days | 5/19 |
| Days Inventory | 220 days | 6/19 |
| Payables Period | 69 days | 4/18 |
| Cash Conversion Cycle | 222 days | 5/17 |
Income Statement
| Metric | PACB | Rank |
|---|---|---|
| Total Revenue | $159M | 11/21 |
| Operating Income | -$133M | 18/21 |
| Net Income | -$131M | 19/21 |
| R&D Expense | $88M | 10/21 |
| SG&A Expense | $130M | 12/20 |
| Cost of Goods Sold | $101M | 9/19 |
Dividend & Shareholder Information
| Metric | PACB | Rank |
|---|---|---|
| Shares Outstanding | 311M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $339M | 45.0% of assets |
| Cash & Short-term Investments | $61M | 8.1% of assets |
| Accounts Receivable | $31M | 4.1% of assets |
| Inventory | $61M | 8.1% of assets |
| Total Liabilities | $785M | |
| Short-term Debt | $50M | 6.6% of assets |
Quarterly Financial Reports
PACB quarterly financials and insider trading
Industry Peers · Laboratory Analytical Instruments
Pacific Biosciences Of California, Inc. (PACB) industry peers
Companies classified under the same SEC industry code as Pacific Biosciences Of California, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PACB Pacific Biosciences Of California, Inc. | ▲ | $538M |
| A Agilent Technologies, Inc. | ▼ | $48.75B |
| WAT Waters Corp /De/ | ▶ | $42.93B |
| ILMN Illumina, Inc. | ▲ | $39.64B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.51B |
| RVTY Revvity, Inc. | ▶ | $17.03B |
| AVTR Avantor, Inc. | ▼ | $11.19B |
| BIO Bio-Rad Laboratories, Inc. | ▶ | $9.46B |
| TXG 10x Genomics, Inc. | ▲ | $9.10B |
| BRKR Bruker Corp | ▲ | $8.35B |
| ALMR Alamar Biosciences, Inc. | ▲ | $1.75B |
| CTKB Cytek Biosciences, Inc. | ▲ | $682M |
| MASS 908 Devices Inc. | ▲ | $465M |
| NAUT Nautilus Biotechnology, Inc. | ▲ | $262M |
| EYPT Eyepoint, Inc. | ▲ | $258M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $235M |
| QTRX Quanterix Corp | ▲ | $136M |
| SEER Seer, Inc. | ▲ | $113M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $42M |
| PRPO Precipio, Inc. | ▲ | $38M |
| HBIO Harvard Bioscience Inc | ▼ | $37M |
| BNGO Bionano Genomics, Inc. | ▲ | $15M |
| LCTC Lifeloc Technologies, Inc | ▲ | $11M |
| ASTC Astrotech Corp | ▶ | $10M |
| SCND Scientific Industries Inc | ▲ | $8M |
Where PACB sits on the market map
Industrial Applications and Services · Laboratory Analytical Instruments
News
Pacific Biosciences Of California, Inc. (PACB) stock news
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.99, marking a -2.93% move from the ...
PacBio teams with TychoBio to advance AI-driven RNA therapeutics
Pacific Biosciences of California PACB recently announced a collaboration with TychoBio, an AI-driven drug discovery company, ...
FAQ
Pacific Biosciences Of California, Inc. (PACB) stock forecast FAQ
What is the Pacific Biosciences Of California, Inc. (PACB) stock forecast?
Our AI ranks Pacific Biosciences Of California, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Pacific Biosciences Of California, Inc. stock predictions?
For PACB, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -14.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -2.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Pacific Biosciences Of California, Inc. forecasts updated?
Pacific Biosciences Of California, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Pacific Biosciences Of California, Inc.'s industry peers?
25 issuers in our coverage, PACB included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.